feed,title,long_url,short_url
SeekingAlpha,Seagen's Tuksya shows sustained survival benefit in HER2-positive breast cancer patients,https://seekingalpha.com/news/3702772,
SeekingAlpha,Cambium Networks prices secondary offering at $48,https://seekingalpha.com/news/3702771,
